Drugs / iratumumab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00059995 | Jan 2003 → Oct 2007 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00298467 | Feb 2006 → ? | lymphoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00284804 | Nov 2005 → May 2008 | Hodgkins lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iratumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00059995 ↗ |
| Known as | MDX-060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00298467 ↗ |
| Action | Inhibit | “inhibits growth of CD30-expressing tumor cells” PMID 17515574 ↗ May 2007 |
| Modality | Monoclonal antibody | “human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody” PMID 17515574 ↗ May 2007 |
| Route | Intravenous | “administered intravenously” PMID 17515574 ↗ May 2007 |
| Target | TNFRSF8 | “Tumor necrosis factor receptor superfamily member 8 other” CHEMBL2108612 ↗ |